Treating BRAFV600E metastatic colorectal patients in 2019: a BEACON of hope?

Christelle de la Fouchardiere


BRAF V600E mutations have been described, since their discovery date in 2002, in about 10% of metastatic colorectal (mCRC) patients (pts) included in prospective clinical trials or retrospective studies (1-3). However, this rate could have been underestimated as suggested in a prospective population-based cohort and confronted by clinical observations (4,5).